APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Selected research

Market Outlook & Growth Opportunities

Global Circulating Tumor Cells Market Outlook and Growth Opportunities 2026

Report ID 173893750421 December 2025206 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cells Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cells Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cells Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cells Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cells Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.

This report provides an overview of the global Circulating Tumor Cells market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Circulating Tumor Cells and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Circulating Tumor Cells revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Circulating Tumor Cells market.

Circulating Tumor Cells Segment by Company

Menarini-Silicon Biosystems

Qiagen (Adnagen)

Advanced Cell Diagnostics

ApoCell

Epic Sciences

Greiner Bio-one GmbH

Cynvenio

SurExamBio-Tech

Fluxion Biosciences

Ikonisys

Hangzhou Watson Biotech

Biocept

CytoTrack

Guangzhou Wondfo Biotech

Celsee

Clearbridge Biomedics

ANGLE plc

Circulating Tumor Cells Segment by Type

CTC Enrichment

CTC Detection

CTC Analysis

Circulating Tumor Cells Segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

Circulating Tumor Cells Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Circulating Tumor Cells status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Circulating Tumor Cells key companies, revenue, market share, and recent developments.

3. To split the Circulating Tumor Cells breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Circulating Tumor Cells market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Circulating Tumor Cells significant trends, drivers, influence factors in global and regions.

6. To analyze Circulating Tumor Cells competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Circulating Tumor Cells industry.

Chapter 3: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Circulating Tumor Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Circulating Tumor Cells in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Circulating Tumor Cells Industry Trends Table 2. Circulating Tumor Cells Industry Drivers Table 3. Circulating Tumor Cells Industry Opportunities and Challenges Table 4. Circulating Tumor Cells Industry Restraints Table 5. Global Circulating Tumor Cells Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Circulating Tumor Cells Revenue Share by Company (2021-2026) Table 7. Global Circulating Tumor Cells Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Circulating Tumor Cells Key Company Manufacturing Base & Headquarters Table 9. Global Circulating Tumor Cells Company, Product Type & Application Table 10. Global Circulating Tumor Cells Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Circulating Tumor Cells by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CTC Enrichment Table 15. Significant Companies of CTC Detection Table 16. Significant Companies of CTC Analysis Table 17. Global Circulating Tumor Cells Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Circulating Tumor Cells Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Circulating Tumor Cells Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Circulating Tumor Cells Sales Value Share by Type (2021-2026) Table 21. Global Circulating Tumor Cells Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Breast Cancer Table 23. Significant Companies of Prostate Cancer Table 24. Significant Companies of Colorectal Cancer Table 25. Significant Companies of Lung Cancer Table 26. Significant Companies of Others Table 27. Global Circulating Tumor Cells Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Circulating Tumor Cells Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Circulating Tumor Cells Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Circulating Tumor Cells Sales Value Share by Application (2021-2026) Table 31. Global Circulating Tumor Cells Sales Value Share by Application (2027-2032) Table 32. Global Circulating Tumor Cells Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Circulating Tumor Cells Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Circulating Tumor Cells Sales Value Share by Region (2021-2026) Table 35. Global Circulating Tumor Cells Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Circulating Tumor Cells Sales Value Share by Region (2027-2032) Table 37. Global Circulating Tumor Cells Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Circulating Tumor Cells Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Circulating Tumor Cells Sales Value Market Share by Country (2021-2026) Table 40. Global Circulating Tumor Cells Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Circulating Tumor Cells Sales Value Market Share by Country (2027-2032) Table 42. Menarini-Silicon Biosystems Company Information Table 43. Menarini-Silicon Biosystems Business Overview Table 44. Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio Table 46. Menarini-Silicon Biosystems Recent Development Table 47. Qiagen (Adnagen) Company Information Table 48. Qiagen (Adnagen) Business Overview Table 49. Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio Table 51. Qiagen (Adnagen) Recent Development Table 52. Advanced Cell Diagnostics Company Information Table 53. Advanced Cell Diagnostics Business Overview Table 54. Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio Table 56. Advanced Cell Diagnostics Recent Development Table 57. ApoCell Company Information Table 58. ApoCell Business Overview Table 59. ApoCell Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. ApoCell Circulating Tumor Cells Product Portfolio Table 61. ApoCell Recent Development Table 62. Epic Sciences Company Information Table 63. Epic Sciences Business Overview Table 64. Epic Sciences Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Epic Sciences Circulating Tumor Cells Product Portfolio Table 66. Epic Sciences Recent Development Table 67. Greiner Bio-one GmbH Company Information Table 68. Greiner Bio-one GmbH Business Overview Table 69. Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio Table 71. Greiner Bio-one GmbH Recent Development Table 72. Cynvenio Company Information Table 73. Cynvenio Business Overview Table 74. Cynvenio Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Cynvenio Circulating Tumor Cells Product Portfolio Table 76. Cynvenio Recent Development Table 77. SurExamBio-Tech Company Information Table 78. SurExamBio-Tech Business Overview Table 79. SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. SurExamBio-Tech Circulating Tumor Cells Product Portfolio Table 81. SurExamBio-Tech Recent Development Table 82. Fluxion Biosciences Company Information Table 83. Fluxion Biosciences Business Overview Table 84. Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Fluxion Biosciences Circulating Tumor Cells Product Portfolio Table 86. Fluxion Biosciences Recent Development Table 87. Ikonisys Company Information Table 88. Ikonisys Business Overview Table 89. Ikonisys Circulating Tumor Cells Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Ikonisys Circulating Tumor Cells Product Portfolio Table 91. Ikonisys Recent Development Table 92. Hangzhou Watson Biotech Company Information Table 93. Hangzhou Watson Biotech Business Overview Table 94. Hangzhou Watson Biotech Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio Table 96. Hangzhou Watson Biotech Recent Development Table 97. Biocept Company Information Table 98. Biocept Business Overview Table 99. Biocept Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Biocept Circulating Tumor Cells Product Portfolio Table 101. Biocept Recent Development Table 102. CytoTrack Company Information Table 103. CytoTrack Business Overview Table 104. CytoTrack Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. CytoTrack Circulating Tumor Cells Product Portfolio Table 106. CytoTrack Recent Development Table 107. Guangzhou Wondfo Biotech Company Information Table 108. Guangzhou Wondfo Biotech Business Overview Table 109. Guangzhou Wondfo Biotech Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio Table 111. Guangzhou Wondfo Biotech Recent Development Table 112. Celsee Company Information Table 113. Celsee Business Overview Table 114. Celsee Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 115. Celsee Circulating Tumor Cells Product Portfolio Table 116. Celsee Recent Development Table 117. Clearbridge Biomedics Company Information Table 118. Clearbridge Biomedics Business Overview Table 119. Clearbridge Biomedics Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 120. Clearbridge Biomedics Circulating Tumor Cells Product Portfolio Table 121. Clearbridge Biomedics Recent Development Table 122. ANGLE plc Company Information Table 123. ANGLE plc Business Overview Table 124. ANGLE plc Circulating Tumor Cells Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 125. ANGLE plc Circulating Tumor Cells Product Portfolio Table 126. ANGLE plc Recent Development Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Circulating Tumor Cells Product Image Figure 2. Global Circulating Tumor Cells Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 4. Global Circulating Tumor Cells Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CTC Enrichment Image Figure 8. CTC Detection Image Figure 9. CTC Analysis Image Figure 10. Global Circulating Tumor Cells Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Circulating Tumor Cells Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Circulating Tumor Cells Sales Value Share by Type (2021-2032) Figure 13. Breast Cancer Image Figure 14. Prostate Cancer Image Figure 15. Colorectal Cancer Image Figure 16. Lung Cancer Image Figure 17. Others Image Figure 18. Global Circulating Tumor Cells Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Circulating Tumor Cells Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Circulating Tumor Cells Sales Value Share by Application (2021-2032) Figure 21. Global Circulating Tumor Cells Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Circulating Tumor Cells Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Circulating Tumor Cells Sales Value (2021-2032) & (US$ Million) Figure 24. North America Circulating Tumor Cells Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Circulating Tumor Cells Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Circulating Tumor Cells Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Circulating Tumor Cells Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Circulating Tumor Cells Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Circulating Tumor Cells Sales Value (2021-2032) & (US$ Million) Figure 30. South America Circulating Tumor Cells Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Circulating Tumor Cells Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Circulating Tumor Cells Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Circulating Tumor Cells Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
Applications
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
Companies covered
  • Menarini-Silicon Biosystems
  • Qiagen (Adnagen)
  • Advanced Cell Diagnostics
  • ApoCell
  • Epic Sciences
  • Greiner Bio-one GmbH
  • Cynvenio
  • SurExamBio-Tech
  • Fluxion Biosciences
  • Ikonisys
  • Hangzhou Watson Biotech
  • Biocept
  • CytoTrack
  • Guangzhou Wondfo Biotech
  • Celsee
  • Clearbridge Biomedics
  • ANGLE plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Circulating Tumor Cells Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Circulating Tumor Cells Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Circulating Tumor Cells Market Dynamics
  1. 2.1 Circulating Tumor Cells Industry Trends
  2. 2.2 Circulating Tumor Cells Industry Drivers
  3. 2.3 Circulating Tumor Cells Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cells Industry Restraints
3 Circulating Tumor Cells Market by Company
  1. 3.1 Global Circulating Tumor Cells Company Revenue Ranking in 2025
  2. 3.2 Global Circulating Tumor Cells Revenue by Company (2021-2026)
  3. 3.3 Global Circulating Tumor Cells Company Ranking (2024-2026)
  4. 3.4 Global Circulating Tumor Cells Company Manufacturing Base and Headquarters
  5. 3.5 Global Circulating Tumor Cells Company Product Type and Application
  6. 3.6 Global Circulating Tumor Cells Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Circulating Tumor Cells Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Circulating Tumor Cells Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Circulating Tumor Cells Market by Type
  1. 4.1 Circulating Tumor Cells Type Introduction
  2. 4.1.1 CTC Enrichment
  3. 4.1.2 CTC Detection
  4. 4.1.3 CTC Analysis
  5. 4.2 Global Circulating Tumor Cells Sales Value by Type
  6. 4.2.1 Global Circulating Tumor Cells Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Circulating Tumor Cells Sales Value by Type (2021-2032)
  8. 4.2.3 Global Circulating Tumor Cells Sales Value Share by Type (2021-2032)
5 Circulating Tumor Cells Market by Application
  1. 5.1 Circulating Tumor Cells Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Circulating Tumor Cells Sales Value by Application
  8. 5.2.1 Global Circulating Tumor Cells Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Circulating Tumor Cells Sales Value by Application (2021-2032)
  10. 5.2.3 Global Circulating Tumor Cells Sales Value Share by Application (2021-2032)
6 Circulating Tumor Cells Regional Value Analysis
  1. 6.1 Global Circulating Tumor Cells Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Circulating Tumor Cells Sales Value by Region (2021-2032)
  3. 6.2.1 Global Circulating Tumor Cells Sales Value by Region: 2021-2026
  4. 6.2.2 Global Circulating Tumor Cells Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Circulating Tumor Cells Sales Value (2021-2032)
  7. 6.3.2 North America Circulating Tumor Cells Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Circulating Tumor Cells Sales Value (2021-2032)
  10. 6.4.2 Europe Circulating Tumor Cells Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Circulating Tumor Cells Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Circulating Tumor Cells Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Circulating Tumor Cells Sales Value (2021-2032)
  16. 6.6.2 South America Circulating Tumor Cells Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Circulating Tumor Cells Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Circulating Tumor Cells Sales Value Share by Country, 2025 VS 2032
7 Circulating Tumor Cells Country-level Value Analysis
  1. 7.1 Global Circulating Tumor Cells Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Circulating Tumor Cells Sales Value by Country (2021-2032)
  3. 7.2.1 Global Circulating Tumor Cells Sales Value by Country (2021-2026)
  4. 7.2.2 Global Circulating Tumor Cells Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Circulating Tumor Cells Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Circulating Tumor Cells Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Circulating Tumor Cells Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Menarini-Silicon Biosystems
  2. 8.1.1 Menarini-Silicon Biosystems Company Information
  3. 8.1.2 Menarini-Silicon Biosystems Business Overview
  4. 8.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio
  6. 8.1.5 Menarini-Silicon Biosystems Recent Developments
  7. 8.2 Qiagen (Adnagen)
  8. 8.2.1 Qiagen (Adnagen) Company Information
  9. 8.2.2 Qiagen (Adnagen) Business Overview
  10. 8.2.3 Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio
  12. 8.2.5 Qiagen (Adnagen) Recent Developments
  13. 8.3 Advanced Cell Diagnostics
  14. 8.3.1 Advanced Cell Diagnostics Company Information
  15. 8.3.2 Advanced Cell Diagnostics Business Overview
  16. 8.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio
  18. 8.3.5 Advanced Cell Diagnostics Recent Developments
  19. 8.4 ApoCell
  20. 8.4.1 ApoCell Company Information
  21. 8.4.2 ApoCell Business Overview
  22. 8.4.3 ApoCell Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ApoCell Circulating Tumor Cells Product Portfolio
  24. 8.4.5 ApoCell Recent Developments
  25. 8.5 Epic Sciences
  26. 8.5.1 Epic Sciences Company Information
  27. 8.5.2 Epic Sciences Business Overview
  28. 8.5.3 Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Epic Sciences Circulating Tumor Cells Product Portfolio
  30. 8.5.5 Epic Sciences Recent Developments
  31. 8.6 Greiner Bio-one GmbH
  32. 8.6.1 Greiner Bio-one GmbH Company Information
  33. 8.6.2 Greiner Bio-one GmbH Business Overview
  34. 8.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio
  36. 8.6.5 Greiner Bio-one GmbH Recent Developments
  37. 8.7 Cynvenio
  38. 8.7.1 Cynvenio Company Information
  39. 8.7.2 Cynvenio Business Overview
  40. 8.7.3 Cynvenio Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cynvenio Circulating Tumor Cells Product Portfolio
  42. 8.7.5 Cynvenio Recent Developments
  43. 8.8 SurExamBio-Tech
  44. 8.8.1 SurExamBio-Tech Company Information
  45. 8.8.2 SurExamBio-Tech Business Overview
  46. 8.8.3 SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  47. 8.8.4 SurExamBio-Tech Circulating Tumor Cells Product Portfolio
  48. 8.8.5 SurExamBio-Tech Recent Developments
  49. 8.9 Fluxion Biosciences
  50. 8.9.1 Fluxion Biosciences Company Information
  51. 8.9.2 Fluxion Biosciences Business Overview
  52. 8.9.3 Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fluxion Biosciences Circulating Tumor Cells Product Portfolio
  54. 8.9.5 Fluxion Biosciences Recent Developments
  55. 8.10 Ikonisys
  56. 8.10.1 Ikonisys Company Information
  57. 8.10.2 Ikonisys Business Overview
  58. 8.10.3 Ikonisys Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ikonisys Circulating Tumor Cells Product Portfolio
  60. 8.10.5 Ikonisys Recent Developments
  61. 8.11 Hangzhou Watson Biotech
  62. 8.11.1 Hangzhou Watson Biotech Company Information
  63. 8.11.2 Hangzhou Watson Biotech Business Overview
  64. 8.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio
  66. 8.11.5 Hangzhou Watson Biotech Recent Developments
  67. 8.12 Biocept
  68. 8.12.1 Biocept Company Information
  69. 8.12.2 Biocept Business Overview
  70. 8.12.3 Biocept Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Biocept Circulating Tumor Cells Product Portfolio
  72. 8.12.5 Biocept Recent Developments
  73. 8.13 CytoTrack
  74. 8.13.1 CytoTrack Company Information
  75. 8.13.2 CytoTrack Business Overview
  76. 8.13.3 CytoTrack Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CytoTrack Circulating Tumor Cells Product Portfolio
  78. 8.13.5 CytoTrack Recent Developments
  79. 8.14 Guangzhou Wondfo Biotech
  80. 8.14.1 Guangzhou Wondfo Biotech Company Information
  81. 8.14.2 Guangzhou Wondfo Biotech Business Overview
  82. 8.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio
  84. 8.14.5 Guangzhou Wondfo Biotech Recent Developments
  85. 8.15 Celsee
  86. 8.15.1 Celsee Company Information
  87. 8.15.2 Celsee Business Overview
  88. 8.15.3 Celsee Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Celsee Circulating Tumor Cells Product Portfolio
  90. 8.15.5 Celsee Recent Developments
  91. 8.16 Clearbridge Biomedics
  92. 8.16.1 Clearbridge Biomedics Company Information
  93. 8.16.2 Clearbridge Biomedics Business Overview
  94. 8.16.3 Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Clearbridge Biomedics Circulating Tumor Cells Product Portfolio
  96. 8.16.5 Clearbridge Biomedics Recent Developments
  97. 8.17 ANGLE plc
  98. 8.17.1 ANGLE plc Company Information
  99. 8.17.2 ANGLE plc Business Overview
  100. 8.17.3 ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ANGLE plc Circulating Tumor Cells Product Portfolio
  102. 8.17.5 ANGLE plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst